CY1117844T1 - Παραγωγα ν-υδροξυλοσουλφοναμιδιου ως νεοι φυσιολογικα χρησιμοι δοτες νιτροξυλιου - Google Patents

Παραγωγα ν-υδροξυλοσουλφοναμιδιου ως νεοι φυσιολογικα χρησιμοι δοτες νιτροξυλιου

Info

Publication number
CY1117844T1
CY1117844T1 CY20161100710T CY161100710T CY1117844T1 CY 1117844 T1 CY1117844 T1 CY 1117844T1 CY 20161100710 T CY20161100710 T CY 20161100710T CY 161100710 T CY161100710 T CY 161100710T CY 1117844 T1 CY1117844 T1 CY 1117844T1
Authority
CY
Cyprus
Prior art keywords
derivatives
nitroxyl donors
physiologically useful
new physiologically
nitroxyl
Prior art date
Application number
CY20161100710T
Other languages
English (en)
Inventor
John P Toscano
Frederick Arthur Brookfield
Andrew D Cohen
Stephen Martin Courtney
Lisa Marie Frost
Vincent Jacob Kalish
Original Assignee
The Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38284031&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1117844(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The Johns Hopkins University filed Critical The Johns Hopkins University
Publication of CY1117844T1 publication Critical patent/CY1117844T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/48—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/14—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/64—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
    • C07C323/67—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfonamide groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/18—Radicals substituted by singly bound hetero atoms other than halogen by sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)

Abstract

Η εφεύρεση σχετίζεται με παράγωγα Ν-υδροξυσουλφοναμιδίου που δωρίζουν νιτροξύλιο (ΗΝΟ) υπό φυσιολογικές συνθήκες και είναι χρήσιμα στη θεραπευτική αντιμετώπιση ή/και πρόληψη της έναρξης ή/και ανάπτυξης νόσων ή παθήσεων που ανταποκρίνονται στη θεραπεία με νιτροξύλιο, συμπεριλαμβανομένης της καρδιακής ανεπάρκειας ή/και της βλάβης από ισχαιμία/επαναιμάτωση. Τα καινοτόμα παράγωγα Ν-υδροξυσουλφοναμιδίου αποδεσμεύουν ΝΗΟ με ελεγχόμενο ρυθμό υπό φυσιολογικές συνθήκες και ο ρυθμός αποδέσμευσης ΗΝΟ ρυθμίζεται διαφοροποιώντας τη φύση και τη θέση των λειτουργικών ομάδων στα παράγωγα Ν-υδροξυσουλφοναμιδίου.
CY20161100710T 2006-03-17 2016-07-20 Παραγωγα ν-υδροξυλοσουλφοναμιδιου ως νεοι φυσιολογικα χρησιμοι δοτες νιτροξυλιου CY1117844T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78355606P 2006-03-17 2006-03-17
EP07753345A EP1998761A1 (en) 2006-03-17 2007-03-16 N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors
EP12155608.8A EP2489350B1 (en) 2006-03-17 2007-03-16 N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors

Publications (1)

Publication Number Publication Date
CY1117844T1 true CY1117844T1 (el) 2017-05-17

Family

ID=38284031

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20141100166T CY1115314T1 (el) 2006-03-17 2014-02-28 Παραγωγα n-υδροξυλσουλφοναμιδιου ως νεοι φυσιολογικως χρησιμοι δοτες νιτροξυλιου
CY20161100710T CY1117844T1 (el) 2006-03-17 2016-07-20 Παραγωγα ν-υδροξυλοσουλφοναμιδιου ως νεοι φυσιολογικα χρησιμοι δοτες νιτροξυλιου
CY20161101084T CY1118237T1 (el) 2006-03-17 2016-10-26 Παραγωγα ν-υδροξυλοσουλφοναμιδιου ως νεοι φυσιολογικα χρησιμοι δοτες νιτροξυλιου

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20141100166T CY1115314T1 (el) 2006-03-17 2014-02-28 Παραγωγα n-υδροξυλσουλφοναμιδιου ως νεοι φυσιολογικως χρησιμοι δοτες νιτροξυλιου

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20161101084T CY1118237T1 (el) 2006-03-17 2016-10-26 Παραγωγα ν-υδροξυλοσουλφοναμιδιου ως νεοι φυσιολογικα χρησιμοι δοτες νιτροξυλιου

Country Status (25)

Country Link
US (11) US8030356B2 (el)
EP (8) EP3124471B1 (el)
JP (4) JP5548869B2 (el)
KR (7) KR102144926B1 (el)
CN (4) CN103435524B (el)
AU (4) AU2007227457B2 (el)
BR (1) BRPI0708804B8 (el)
CA (1) CA2645988C (el)
CY (3) CY1115314T1 (el)
DK (2) DK2586435T3 (el)
ES (4) ES2448807T3 (el)
HK (2) HK1174531A1 (el)
HU (2) HUE029309T2 (el)
IL (3) IL193839A (el)
LT (1) LT2586435T (el)
MX (3) MX368352B (el)
NO (2) NO342523B1 (el)
NZ (4) NZ595770A (el)
PL (3) PL2586434T3 (el)
PT (3) PT2586434T (el)
RU (2) RU2448087C2 (el)
SG (2) SG170737A1 (el)
SI (3) SI2489350T1 (el)
TR (1) TR200807066T1 (el)
WO (1) WO2007109175A1 (el)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007002444A1 (en) * 2005-06-23 2007-01-04 Johns Hopkins University Thiol-sensitive positive inotropes
MX368352B (es) 2006-03-17 2019-09-30 Univ Johns Hopkins Derivados de n-hidroxilsulfonamida como nuevos donantes de nitroxilo fisiologicamente utiles.
CA2699567C (en) 2007-09-26 2018-01-09 Cardioxyl Pharmaceuticals, Inc. N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors
JP5654450B2 (ja) 2008-05-07 2015-01-14 カルディオキシル ファーマシューティカルズ，インク． ニトロキシル供与体としての新規ニトロソ化合物およびその使用方法
US20100234827A1 (en) * 2009-03-13 2010-09-16 Sigg Daniel C Method of treating heart failure
US20110160200A1 (en) * 2009-11-23 2011-06-30 Cardioxyl Pharmaceuticals, Inc. Nitroxyl Progenitors for the Treatment of Pulmonary Hypertension
ES2719101T3 (es) * 2009-12-07 2019-07-08 Univ Johns Hopkins Derivados de hidroxilamina N-acilados y derivados de hidroxilamina o-acilados
AU2010328230B2 (en) 2009-12-07 2016-06-02 Cardioxyl Pharmaceuticals, Inc. Bis-acylated hydroxylamine derivatives
WO2013059194A1 (en) * 2011-10-17 2013-04-25 Johns Hopkins University Meldrum 's acid, barbituric acid and pyrazolone derivatives substituted with hydroxylamine as hno donors
EP2914579A1 (en) 2012-11-01 2015-09-09 The Johns Hopkins University Controlled hno release through intramolecular cyclization-elimination
HUE046722T2 (hu) 2013-01-18 2020-03-30 Cardioxyl Pharmaceuticals Inc Javított terápiás indexû nitroxil donorok
EP2764868A1 (en) 2013-02-08 2014-08-13 Friedrich-Alexander-Universität Erlangen-Nürnberg Combination of nitroprusside and a sulfide salt as an HNO-releasing therapeutic for the treatment or prevention of cardiovascular diseases
EP3126329B1 (en) 2014-01-17 2019-05-29 Cardioxyl Pharmaceuticals Inc. N-hydroxymethanesulfonamide nitroxyl donors
ES2749682T3 (es) 2014-05-27 2020-03-23 Cardioxyl Pharmaceuticals Inc Derivados de pirazolona como donadores de nitroxilo
WO2015183838A1 (en) 2014-05-27 2015-12-03 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives as nitroxyl donors
US9464061B2 (en) 2014-05-27 2016-10-11 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives
WO2016210392A1 (en) * 2015-06-26 2016-12-29 The Johns Hopkins University N-substituted hydroxamic acids with carbon-based leaving groups as efficient hno donors and uses thereof
KR20180070672A (ko) * 2015-10-19 2018-06-26 카르디옥실 파마슈티칼스 인코포레이티드 니트록실 공여자로서의 n-히드록실술폰아미드 유도체
KR20180063326A (ko) * 2015-10-19 2018-06-11 카르디옥실 파마슈티칼스 인코포레이티드 니트록실 공여자로서의 피라졸론 유도체
JP6816763B2 (ja) 2016-03-31 2021-01-20 住友化学株式会社 複素環化合物
ES2878060T3 (es) 2016-07-28 2021-11-18 Univ Johns Hopkins Acidos hidroxámicos O-sustituidos
SG10202107533RA (en) 2017-01-03 2021-08-30 Cardioxyl Pharmaceuticals Inc Method of administering nitroxyl donating compounds
CN114230495B (zh) * 2021-11-24 2023-01-06 海南大学 一种氢化亚硝酰供体及其制备方法
CN114195731A (zh) * 2021-11-24 2022-03-18 海南大学 一种氢化亚硝酰供体化合物及其制备方法

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1017976A (en) 1911-08-25 1912-02-20 Rudolph Koch Automatic mail-bag catcher and deliverer.
US3751255A (en) * 1972-03-24 1973-08-07 Eastman Kodak Co Photosensitive and thermosensitive element, composition and process
JPS567710A (en) 1979-06-28 1981-01-27 Sansho Seiyaku Kk Whitening cosmetic
US4539321A (en) 1981-10-26 1985-09-03 William H. Rorer, Inc. 5-Diaza-aryl-3-substituted pyridone compounds
DE3583799D1 (de) 1985-01-11 1991-09-19 Abbott Lab Ltd Feste zubereitung mit langsamer freisetzung.
US4663351A (en) 1985-08-23 1987-05-05 Berlex Laboratories, Inc. Dobutamine tri-isobutyric acid ester and the use thereof as a cardiotonic agent
US4798824A (en) 1985-10-03 1989-01-17 Wisconsin Alumni Research Foundation Perfusate for the preservation of organs
JPH01221371A (ja) * 1988-02-29 1989-09-04 Hokko Chem Ind Co Ltd 環状オキシアミン誘導体の製造方法
JPH01221372A (ja) 1988-03-01 1989-09-04 Hokko Chem Ind Co Ltd 環状アシルヒドロキシルアミン誘導体
JPH0221372A (ja) 1988-07-08 1990-01-24 Sharp Corp はんだ付検査装置
JPH0446169A (ja) * 1990-06-14 1992-02-17 Mitsubishi Petrochem Co Ltd 新規なベンゾフラン誘導体及びそれを含有する除草剤
JP2773959B2 (ja) 1990-07-10 1998-07-09 信越化学工業株式会社 大腸内放出性固形製剤
JPH04321671A (ja) * 1991-04-17 1992-11-11 Mitsubishi Petrochem Co Ltd カルバモイルトリアゾール誘導体およびそれを有効成分とする除草剤
EP0595546B1 (en) 1992-10-28 1996-03-20 Shionogi & Co., Ltd. Benzylidene derivatives
JP2728357B2 (ja) * 1992-10-28 1998-03-18 塩野義製薬株式会社 ベンジリデン誘導体
JPH09165365A (ja) * 1995-09-27 1997-06-24 Ono Pharmaceut Co Ltd スルホンアミド誘導体
JPH10142729A (ja) * 1996-11-05 1998-05-29 Fuji Photo Film Co Ltd 熱現像画像記録材料
WO1999021554A1 (fr) * 1997-10-24 1999-05-06 Shionogi & Co., Ltd. Agent anti-ulcereux
AU741180B2 (en) * 1997-10-24 2001-11-22 Shionogi & Co., Ltd. Antirheumatic
ATE213246T1 (de) * 1997-11-12 2002-02-15 2-phenyl-substituierte imidazotriazinone als phosphodiesterase inhibitoren
UA73092C2 (uk) 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
EP1101490B1 (en) 1998-07-28 2005-04-13 Tanabe Seiyaku Co., Ltd. Preparation capable of releasing drug at target site in intestine
LT4727B (lt) 1998-12-29 2000-11-27 Jonas Šarlauskas 5-pakeisti sulfamoilbenzimidazol-2-ilkarbamino rūgščių metilo esteriai, turintys antihelmintinį aktyvumą
ATE311363T1 (de) * 1999-01-13 2005-12-15 Warner Lambert Co Sulfohydroxamsäure and sulfohydroxamate und ihre verwendung als mek-inhibitoren
GB9918684D0 (en) * 1999-08-09 1999-10-13 Novartis Ag Organic compounds
RU2002107998A (ru) 1999-09-01 2003-11-10 АВЕНТИС ФАРМА ДОЙЧЛАНД ГмбХ (DE) Сульфонилкарбоксамидные производные, способ их получения и их применение в качестве лекарственных средств
DOP2000000109A (es) * 1999-12-23 2002-08-30 Gerald Kleymann Derivados de tiazolilamida
JP2002072459A (ja) 2000-08-28 2002-03-12 Toyo Gosei Kogyo Kk 光酸発生剤及びそれを含有する感光性樹脂組成物
GB0114223D0 (en) 2001-06-12 2001-08-01 Ici Plc Catalytic oxidation process
US20040038947A1 (en) * 2002-06-14 2004-02-26 The Gov. Of The U.S. Of America As Represented By The Sec. Of The Dept. Of Health & Human Services Method of treating ischemia/reperfusion injury with nitroxyl donors
US6936639B2 (en) 2002-08-21 2005-08-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nitroxyl progenitors in the treatment of heart failure
US20040121399A1 (en) * 2002-12-20 2004-06-24 International Business Machines Corporation Substrate bound linker molecules for the construction of biomolecule microarrays
MXPA06001674A (es) * 2003-08-12 2006-05-12 3M Innovative Properties Co Compuestos que contienen imidazo hidroxilamina-sustituidos.
CN1906192A (zh) * 2003-11-14 2007-01-31 3M创新有限公司 羟胺取代的咪唑环化合物
EP1694686A1 (en) * 2003-12-19 2006-08-30 Takeda San Diego, Inc. Kinase inhibitors
CA2554771A1 (en) 2004-01-30 2005-08-18 Johns Hopkins University Nitroxyl progenitor compounds and methods of use
EP1846439A2 (en) 2005-01-31 2007-10-24 The Johns Hopkins University Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants
WO2007002444A1 (en) * 2005-06-23 2007-01-04 Johns Hopkins University Thiol-sensitive positive inotropes
MX368352B (es) 2006-03-17 2019-09-30 Univ Johns Hopkins Derivados de n-hidroxilsulfonamida como nuevos donantes de nitroxilo fisiologicamente utiles.
CA2699567C (en) 2007-09-26 2018-01-09 Cardioxyl Pharmaceuticals, Inc. N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors
HUE046722T2 (hu) 2013-01-18 2020-03-30 Cardioxyl Pharmaceuticals Inc Javított terápiás indexû nitroxil donorok

Also Published As

Publication number Publication date
HK1174531A1 (en) 2013-06-14
EP2586435B1 (en) 2016-09-14
NZ700984A (en) 2016-05-27
MX368352B (es) 2019-09-30
CN103435524B (zh) 2016-02-10
US20160002156A1 (en) 2016-01-07
CY1115314T1 (el) 2017-01-04
US10179765B2 (en) 2019-01-15
HUE030920T2 (en) 2017-06-28
KR20140041941A (ko) 2014-04-04
US20070299107A1 (en) 2007-12-27
CN109438298A (zh) 2019-03-08
AU2007227457A1 (en) 2007-09-27
CN101472576B (zh) 2013-04-17
AU2016201037A1 (en) 2016-03-10
US20210053915A1 (en) 2021-02-25
KR20090058476A (ko) 2009-06-09
PL2489350T3 (pl) 2014-08-29
SI2489350T1 (sl) 2014-05-30
JP6060139B2 (ja) 2017-01-11
MX342895B (es) 2016-10-18
CN101472576A (zh) 2009-07-01
KR20160128447A (ko) 2016-11-07
IL217739A (en) 2016-09-29
PT2586435T (pt) 2016-12-27
ES2448807T3 (es) 2014-03-17
IL238271A (en) 2017-05-29
US9725410B2 (en) 2017-08-08
US10487049B2 (en) 2019-11-26
IL217739A0 (en) 2012-03-29
EP2489350A1 (en) 2012-08-22
NZ570971A (en) 2011-11-25
SI2586434T1 (sl) 2016-09-30
EP3124471A1 (en) 2017-02-01
PL2586435T3 (pl) 2017-06-30
EP3693363A1 (en) 2020-08-12
CA2645988C (en) 2017-01-10
US10829445B2 (en) 2020-11-10
BRPI0708804B1 (pt) 2019-12-17
RU2448087C2 (ru) 2012-04-20
EP1998761A1 (en) 2008-12-10
ES2600518T3 (es) 2017-02-09
US11306056B2 (en) 2022-04-19
KR102144926B1 (ko) 2020-08-14
ES2811258T3 (es) 2021-03-11
IL193839A (en) 2015-04-30
AU2017221796A1 (en) 2017-09-21
KR20150091427A (ko) 2015-08-10
KR20180082639A (ko) 2018-07-18
JP5548869B2 (ja) 2014-07-16
CN103435524A (zh) 2013-12-11
JP5764590B2 (ja) 2015-08-19
JP2013144686A (ja) 2013-07-25
ES2576292T3 (es) 2016-07-06
NO342523B1 (no) 2018-06-04
PT2489350E (pt) 2014-03-10
RU2011152369A (ru) 2013-06-27
US20190144380A1 (en) 2019-05-16
BRPI0708804B8 (pt) 2021-05-25
JP2015096525A (ja) 2015-05-21
US9969684B2 (en) 2018-05-15
US20170022154A1 (en) 2017-01-26
WO2007109175A1 (en) 2007-09-27
KR20190096457A (ko) 2019-08-19
HK1179509A1 (zh) 2013-10-04
JP2009530303A (ja) 2009-08-27
RU2616292C2 (ru) 2017-04-14
LT2586435T (lt) 2016-12-12
US20170305847A1 (en) 2017-10-26
KR102011703B1 (ko) 2019-08-19
US9221780B2 (en) 2015-12-29
AU2013201667A1 (en) 2013-04-11
NO343986B1 (no) 2019-08-05
EP3124471B1 (en) 2020-06-03
SG10201503828QA (en) 2016-10-28
BRPI0708804A2 (pt) 2011-06-14
EP2586434B1 (en) 2016-04-27
EP2586433A1 (en) 2013-05-01
PL2586434T3 (pl) 2016-10-31
US9487498B2 (en) 2016-11-08
EP2489350B1 (en) 2013-12-04
JP2017057190A (ja) 2017-03-23
SI2586435T1 (sl) 2016-12-30
SG170737A1 (en) 2011-05-30
NO20084355L (no) 2008-12-11
PT2586434T (pt) 2016-08-05
MX2008011643A (es) 2009-02-10
KR20140147155A (ko) 2014-12-29
AU2016201037B2 (en) 2017-09-14
EP2596785A1 (en) 2013-05-29
ES2576292T7 (es) 2022-08-24
EP2586435A1 (en) 2013-05-01
RU2008141151A (ru) 2010-04-27
CA2645988A1 (en) 2007-09-27
CN104672115A (zh) 2015-06-03
CN104672115B (zh) 2018-11-23
DK2489350T3 (en) 2014-03-03
NO20180624A1 (no) 2008-12-11
TR200807066T1 (tr) 2009-11-23
DK2586435T3 (en) 2017-01-09
US20110306614A1 (en) 2011-12-15
CY1118237T1 (el) 2017-06-28
AU2007227457B2 (en) 2013-03-28
EP2586434A1 (en) 2013-05-01
US20180244610A1 (en) 2018-08-30
US20200087253A1 (en) 2020-03-19
EP2586434B3 (en) 2022-04-06
US20140336396A1 (en) 2014-11-13
USRE45314E1 (en) 2014-12-30
KR101473718B1 (ko) 2014-12-17
AU2017221796B2 (en) 2019-10-03
KR101595781B1 (ko) 2016-02-19
KR101878816B1 (ko) 2018-07-16
US8030356B2 (en) 2011-10-04
NZ595770A (en) 2013-04-26
NZ609381A (en) 2014-10-31
HUE029309T2 (en) 2017-02-28
CN109438298B (zh) 2021-10-08

Similar Documents

Publication Publication Date Title
CY1117844T1 (el) Παραγωγα ν-υδροξυλοσουλφοναμιδιου ως νεοι φυσιολογικα χρησιμοι δοτες νιτροξυλιου
CY1120073T1 (el) Παραγωγα πυραζολο-αμινοπυριμιδινης ως ρυθμιστες της lrrk2
CY1124446T1 (el) Μορφες δοσολογιας της ρουξολιτινιμπης παρατεταμενης αποδεσμευσης
CY1117776T1 (el) Εναντιομερη ενωσεων σπειρο-οξινδολιου και οι χρησεις τους ως θεραπευτικοι παραγοντες
MX2010003232A (es) Derivados de n-hidroxisulfonamida como nuevos donadores de nitroxilo fisiologicamente utiles.
CY1121724T1 (el) Ενωσεις για την αντιμετωπιση καρκινου
CY1117719T1 (el) Παραγωγα αμινοπυριμιδινης ως διαμορφωτες της lrrk2
CY1120258T1 (el) Ενωσεις ετεροδικυκλο-υποκατεστημενης-[1,2,4]τριαζολο [1,5-c]κιναζολιν-5-αμινης καταλληλες για αγωγη ή προληψη διαταραχων του κεντρικου νευρικου συστηματος
CY1121030T1 (el) Προφαρμακα πυριδονο αμιδιων χρησιμα ως διαμορφωτες διαυλων νατριου
CY1118135T1 (el) Παραγωγα 2-(φαινυλο ή πυριδ-3-υλο) αμινοπυριμιδινης ως ρυθμιστες κινασης lrrk2 για τη θεραπευτικη αντιμετωπιση της νοσου του parkinson
CY1113112T1 (el) Παραγωγα θειενοπυριδονης ως ενεργοποιητες της πρωτεϊνικης κινασης (αμρκ) που ενεργοποιουνται απο το amρ
CY1118129T1 (el) 5-αλκυνυλ-πυριμιδινες
CY1119252T1 (el) Νεα παραγωγα 1-βενζυλο-3 -υδροξυμεθυλινδαζολης και χρηση αυτων στη θεραπεια νοσων που βασιζονται στην εκφραση των cx3cr1 και ρ40
CY1115836T1 (el) Παραγωγα πυραζινονης και η χρηση τους στη θεραπευτικη αντιμετωπιση παθησεων των πνευμονων
CY1117312T1 (el) Θεραπευτικη αγωγη συνουκλεϊνοπαθειων
CY1115945T1 (el) Παραγωγα πυραζολοκινολινονης, η παρασκευη τους και η θεραπευτικη τους χρηση
CY1117626T1 (el) Παραγωγα 1-ετερυκυκλυλ-1,5-διϋδρο-πυραζολο[3,4-d]πυραμιδιν-4-ονης και η χρηση αυτων ως διαμορφωτες toy pde9a
CY1117183T1 (el) Διακλαδισμενα παραγωγα 3-φαινυλοπροπιονικου οξεος και η χρηση τους
CY1111757T1 (el) Παραγωγα ξανθινης ως εκλεκτικοι αναστολεις ημ74α
CY1118362T1 (el) Ανταγωνιστες υποδοχεων cgrp αζαϊνδανιου καρβοξαμιδιου πιπεριδινονης
PE20160120A1 (es) Derivados de nucleosido 4'-fluoro-2'-metilo sustituido
PA8635301A1 (es) Derivados sustituidos del dioxido de oxazolbenzoisotiazol, procedimiento para su preparacion y su uso
CY1110990T1 (el) Παραγωγα αδενοσινης ως αγωνιστες υποδοχεων α2α
CY1117326T1 (el) Παραγωγο κατεχολαμινης χρησιμο για τη θεραπεια ασθενειας parkinson
CY1109644T1 (el) 2,4-διαμινο-πυριμιδινες ως αναστολεις audora